Limitations of monotherapy trials in epilepsy
Related Experiment Video
Updated: Sep 25, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
1Department of Neurology, Washington University Epilepsy Program, Washington University, St. Louis, MO 63110, USA.
Abstract:
Monotherapy is considered optimal management for most patients with epilepsy, but designing monotherapy trials in epilepsy has proved to be a complex endeavor. Consideration of the validity of evidence for efficacy, potential risks to patients, clinical applicability of results, and effects of dosing and titration rates on efficacy and tolerability creates unique challenges. This article reviews pertinent aspects of trials of conversion to monotherapy in refractory patients and equivalence trials in newly diagnosed patients to better understand their limitations. Despite the inherent difficulties in designing monotherapy trials in epilepsy, previous monotherapy studies have provided important information for clinical management with new treatments.
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Drug Therapy
Antianxiety Medications
